Heart failure in older people: Causes, diagnosis and treatment

Age and Ageing

Volumn 31, Issue 1, 2002, Pages 29-36

  Abdelhafiz, Ahmed H ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Congestive heart failure; Diastolic cardiac dysfunction; Systolic cardiac dysfunction

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOOP DIURETIC AGENT; LOSARTAN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE; VALSARTAN; VERAPAMIL;

AGED; BODY WEIGHT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAGNOSTIC TEST; DIETARY INTAKE; DISEASE EXACERBATION; DISEASE MARKER; FAMILY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REVIEW; SOCIAL SUPPORT; SURVIVAL; SYMPTOMATOLOGY; UNITED KINGDOM; VALVULAR HEART DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; QUALITY OF LIFE;

EID: 0036187726     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/31.1.29     Document Type: Review

References (78)

1. Hospitalization of patients with heart failure: National hospital discharge survey 1985-1995
2. Epidemiology, aetiology and prognosis of heart failure
3. Epidemiology of heart failure
4. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
5. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
6. Trends in the incidence of myocardial infarction and in mortality due to coronary artery disease
7. An evaluation of the cost of heart failure to the National Health Service in the UK
8. Perindopril for elderly people with chronic heart failure: The PEP-CHF study
9. The epidemiology of heart failure: The Framingham study
10. Valvular and congenital heart disease
11. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks
12. Iatrogenic congestive heart failure in older adults: Clinical course and prognosis
13. Nonsteroidal anti-inflammatory drugs
14. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril
15. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An under-recognized public health problem
16. Epidemiology and pathophysiology of heart failure
17. Guidelines for the diagnosis of heart failure
18. Acute confusion in elderly medical patients
19. How to use natriuretic peptide levels for diagnosis and prognosis
20. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea
21. Biochemical detection of left-ventricular systolic dysfunction
22. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of hemodynamic and neuroendocrine effects of tailored versus empirical therapy
23. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
24. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study
25. Congestive heart failure with normal systolic function
26. Intact systolic left ventricular function in clinical congestive heart failure
27. Congestive heart failure in the community: A study of all incident cases in Olmsted County, Minnesota, in 1991
28. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort
29. Diastolic dysfunction in elderly patients with congestive heart failure
30. Prognosis of congestive heart failure in elderly patients with normal versus abnormal left ventricular systolic function associated with coronary artery disease
31. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis? A prospective descriptive study
32. Hypertrophic cardiomegaly in the elderly: A frequently misdiagnosed disease
33. Left ventricular function in hospitalized geriatric patients
34. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
35. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS)
36. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischemic heart disease
37. Safety and efficacy of carvedilol in severe heart failure
38. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
39. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
40. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial
41. Effects of controlled-release metoprolol on total mortality, hospitalization and well-being in patients with heart failure: The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
42. Influence of carvedilol on hospitalizations in heart failure: Incidence, resource utilization and costs
43. Effect of carvedilol on survival in severe chronic heart failure
44. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial
45. Effects of enalapril on mortality in severe congestive heart failure: Results of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS)
46. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
47. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
48. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
49. Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
50. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I
51. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure
52. Losartan in heart failure: Hemodynamic effects and tolerability
53. Randomised trial of losartan versus captopril in patients over 65 with heart failure
54. Losartan heart failure survival study: ELITE II
55. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
56. Additive effects of losartan and enalapril on blood pressure and plasma active renin
57. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects
58. Comparisons of candesartan, enalapril and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study
59. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design
60. A rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
61. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design
62. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
63. The effect of digoxin on mortality and morbidity in patients with heart failure
64. Systolic versus diastolic heart failure: Therapeutic considerations
65. Improvement of diastolic function after reversal of left ventricular hypertrophy induced by long-term antihypertensive treatment with teratolol
66. Progression of left ventricular mass is accompanied by improvement in rapid left ventricular filling following antihypertensive therapy with metoprolol
67. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: Comparison with enalapril
68. Prevalence, clinical features and prognosis of diastolic heart failure. An epidemiological perspective
69. The natural history of isolated left ventricular diastolic dysfunction
70. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction-prevalence and mortality in a population-based cohort
71. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure
72. Nurse led, multidisciplinary intervention in chronic heart failure
73. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: A randomized controlled study
74. Effects of education and support on self-care and resource utilization in patients with heart failure
75. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study
76. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension
77. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial
78. Do we practice geriatric cardiology?